Find a Provider

Edward A. Stadtmauer, MD

Edward A. Stadtmauer, MD Physician

Section Chief, Hematologic Malignancies
Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Stadtmauer is a Penn Medicine employed physician.

About Dr. E Stadtmauer

Recognized annually in Philadelphia Magazine's Top Docs issue from 2005 - 2008, 2011, 2013 - 2015

Recognized by America's Top Doctors, 2007, 2008, 2010, 2011-14

Recognized by Best Doctors in America 2003-2004, 2005-2006, 2007-2008, 2009-2010, 2011-2012, 2013-2014

Clinical Specialties


  • Medicine
    • Hematology
    • Medical Oncology

Programs & Services:

  • Cancer
    • Amyloidosis Program
    • Bone Marrow Transplant and Stem Cell Transplant Program
    • Leukemia
    • Lymphoma
    • Multiple Myeloma
  • Hematology-Oncology
    • Classical (Non-Malignant) Hematology Program

Board Certification:

  • Hematology, 1988
  • Internal Medicine, 1986
  • Medical Oncology, 1989

Conditions & Treatments:

  • acute leukemia
  • Acute Lymphocytic Leukemia in Adults (ALL)
  • Acute Myeloid Leukemia (AML)
  • allogeneic transplant
  • Blood Cancer
  • bone marrow transplant
  • breast transplant
  • chronic leukemia
  • Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
  • Chronic Myeloid Leukemia (CML)
  • germ cell transplant
  • Hodgkin Lymphoma
  • Hodgkin's lymphoma
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • myelodysplasia
  • Myeloproliferative Neoplams (MPN)
  • Non-Hodgkin Lymphoma
  • non-Hodgkin's lymphoma
  • stem cell transplant
  • Waldenstrom macroglobulinemia

Clinical Interests

Myeloma, Leukemia, Lymphoma and Bone Marrow and Stem Cell Transplant

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: University of Pennsylvania School of Medicine
Residency: Bronx Municipal Hospital - Albert Einstein College
Fellowship: Hospital of the University of Pennsylvania


American College of Physicians, Fellow, National American Federation for Clinical Research, National American Society for Blood and Marrow Transplantation, National American Society of Clinical Oncology, National American Society of Hematology, National Autologous Bone Marrow Transplant Registry (ABMTR/CIBMTR), National Bone Marrow Transplant Clinical Trials Network, National Eastern Cooperative Oncology Group, National Foundation for the Accreditation of Hematopoietic Cell Therapy, National International Myeloma Working Group, International Membership in National Scientific Review Panels, National NIAID Hematopoietic Stem Cell Transplantation Data Safety Monitoring Board (HSCT DSMB), National


Dr. Stadtmauer is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.


Research Interests:

Clinical trials, Bone Marrow Transplant

Selected Publications:

Waxman, A J; Mick, R; Garfall, A L; Cohen, A; Vogl, D T; Stadtmauer, E A; Weiss, B M.: Classifying ultra-high risk smoldering myeloma. Leukemia 29 (3): 751-3,2015.

Alsina, Melissa; Becker, Pamela S; Zhong, Xiaobo; Adams, Alexia; Hari, Parameswaran; Rowley, Scott; Stadtmauer, Edward A; Vesole, David H; Logan, Brent; Weisdorf, Daniel; Qazilbash, Muzaffar; Popplewell, Leslie L; McClune, Brian; Bensinger, William; Riches, Marcie; Giralt, Sergio A; Pasquini, Marcelo C; Resource for Clinical Investigation in Blood and Marrow Transplantation.: Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biology of Blood & Marrow Transplantation 20 (8): 1183-9,2014.

Vogl, Dan T; Stadtmauer, Edward A; Tan, Kay-See; Heitjan, Daniel F; Davis, Lisa E; Pontiggia, Laura; Rangwala, Reshma; Piao, Shengfu; Chang, Yunyoung C; Scott, Emma C; Paul, Thomas M; Nichols, Charles W; Porter, David L; Kaplan, Janeen; Mallon, Gayle; Bradner, James E; Amaravadi, Ravi K.: Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy 10 (8): 1380-90,2014.

Rapoport Aaron P, Aqui Nicole A, Stadtmauer Edward A, Vogl Dan T, Xu Yin Yan, Kalos Michael, Cai Ling, Fang Hong-Bin, Weiss Brendan M, Badros Ashraf, Yanovich Saul, Akpek Gorgun, Tsao Patricia, Cross Alan, Mann Dean, Philip Sunita, Kerr Naseem, Brennan Andrea, Zheng Zhaohui, Ruehle Kathleen, Milliron Todd, Strome Scott E, Salazar Andres M, Levine Bruce L, June Carl H: Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clinical cancer research : an official journal of the American Association for Cancer Research 20 (5): 1355-65,2014.

Chng W J, Dispenzieri A, Chim C-S, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel J S, Sonneveld P, Cavo M, Usmani S, Durie B G M, Avet-Loiseau H: IMWG consensus on risk stratification in multiple myeloma. Leukemia 28 (2): 269-77,2014.

Mulligan George, Lichter David I, Di Bacco Alessandra, Blakemore Stephen J, Berger Allison, Koenig Erik, Bernard Hugues, Trepicchio William, Li Bin, Neuwirth Rachel, Chattopadhyay Nibedita, Bolen Joseph B, Dorner Andrew J, van de Velde Helgi, Ricci Deborah, Jagannath Sundar, Berenson James R, Richardson Paul G, Stadtmauer Edward A, Orlowski Robert Z, Lonial Sagar, Anderson Kenneth C, Sonneveld Pieter, San Miguel Jesús F, Esseltine Dixie-Lee, Schu Matthew: Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood 123 (5): 632-9,2014.

Micallef Ivana N, Stiff Patrick J, Stadtmauer Edward A, Bolwell Brian J, Nademanee Auayporn P, Maziarz Richard T, Partisano Angela M, Marulkar Sachin, DiPersio John F: Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients =60 and American journal of hematology 88 (12): 1017-23,2013.

Jakubowiak A J, Siegel D S, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu F J, Somlo G, Zonder J, Song K, Stewart A K, Stadtmauer E, Harrison B L, Wong A F, Orlowski R Z, Jagannath S: Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia 27 (12): 2351-6,2013.

Kaufman Jonathan L, Niesvizky Ruben, Stadtmauer Edward A, Chanan-Khan Asher, Siegel David, Horne Heather, Wegener William A, Goldenberg David M: Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. British journal of haematology 163 (4): 478-86,2013.

Academic Contact Info

2 Perelman Center for Advanced Medicine
34th and Civic Center Bld

Philadelphia, PA 19104
Phone: (215) 662-7910
Fax: (215) 662-4064
Patient appointments: 800-789-PENN (7366)

Related Links